Quality of life, treatment satisfaction, and treatment preference associated with use of a pen device delivering a premixed 70/30 insulin aspart suspension (aspart protamine suspension/soluble aspart) versus alternative treatment strategies.
Rubin
Richard R
RR
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Peyrot
Mark
M
D000368:Aged; D000704:Analysis of Variance; D001786:Blood Glucose / Q000187:drug effects; D015331:Cohort Studies; D003924:Diabetes Mellitus, Type 2 / Q000175:diagnosis / Q000188:drug therapy*; D004209:Disposable Equipment; D016503:Drug Delivery Systems; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D007279:Injections, Subcutaneous; D007328:Insulin / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D061267:Insulin Aspart; D008297:Male; D008875:Middle Aged; D017060:Patient Satisfaction; D011336:Probability; D011788:Quality of Life; D012307:Risk Factors; D012995:Solubility; D011795:Surveys and Questionnaires; D016896:Treatment Outcome
D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin; D061267:Insulin Aspart